Contrast medium composition and method of bio imagination using the same

Patent metadata

Field	Value
Publication number	US-9669114-B2
Application number	US-201414197322-A
Country	US
Kind code	B2
Filing date	Mar 5, 2014
Priority date	Mar 7, 2013
Publication date	Jun 6, 2017
Grant date	Jun 6, 2017

Abstract

The present invention relates to contrast medium composition and a method of bio imagination using the same. The contrast medium composition of the present invention includes a biomolecule, DNA nanostructure, as an active ingredient, is fundamentally non-cytotoxic and non-immunogenic and is not likely to induce safety problems that may be observed in other organic or inorganic contrast medium composition. In addition, the contrast medium composition of the present invention not only facilitates diagnosis of disease through sufficient contrast enhancement effect by showing excellent cellular uptake and intracellular stability and can visualize even SLNs which is difficult to be visualized traditionally, so can judge metastasis of cancer easily and apply lower invasive treatment.

First claim

What is claimed is:

1. A method of bio-imaging a sentinel lymph node, comprising:
(a) administering parenterally to a subject a contrast medium composition comprising a DNA nanocage, a label, and a pharmaceutically acceptable excipient, wherein the DNA nanocage has a tetrahedral structure, and wherein the tetrahedral structure has 6 sides each consisting of duplex oligonucleotide; and
(b) detecting a real-time signal derived from the label in the sentinel lymph node of the subject, wherein the detection of the real-time signal indicates development or progression of cancer or cancer metastasis.

2. The method according to claim 1 , wherein the label is selected from the group consisting of diatrizoate, metrizoate, ioxaglate, iopamidol, iohexol, ioxilan, iopromide, iodixanol, barium based dye, GASTROGRAFIN®, a fluorescent substance, and an isotope.

3. The method according to claim 1 , wherein the real-time signal is visualized using any one selected from a fluorescence imaging, an optical imaging, a radiation imaging, a computed tomography (CT) or a MRI bio-imaging method.

4. The method according to claim 1 , wherein the method is carried out in vivo.

5. The method according to claim 1 , wherein the step of detecting the real-time signal occurs from 2 to 10 hours after the step of administering.

6. The method according to claim 1 , wherein the DNA nanocage has a hydrodynamic diameter range of 6-10 nm.

7. The method according to claim 1 , wherein the contrast medium composition has a stability in serum greater than 70% for 3 to 7 hours.

8. The method according to claim 1 , wherein the contrast medium composition consists essentially of the DNA nanocage, the label, and the pharmaceutically acceptable excipient.

9. The method according to claim 1 , wherein the oligonucleotide is a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1 to 8.

10. The method according to claim 2 , wherein the barium based dye is barium sulfate.

11. The method according to claim 2 , wherein the fluorescent substance is selected from the group consisting of indocyanine, NIR (near infrared) dye, fluorescein, phycoeryhrin, rhodamine, lissamine, Cy3, Cy5, chromophore, chemical luminophore, horseradish peroxidase, and alkaline phosphatase.

Assignees

• Korea Inst Sci & Tech

Inventors

• Ahn Dae Ro
• Kim Se Hoon

Classifications

• A61K49/0093 Primary

  Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle · CPC title

• A61K49/0054

  Macromolecular compounds, i.e. oligomers, polymers, dendrimers · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61K49/0002

  General or multifunctional contrast agents, e.g. chelated agents · CPC title

• A61K49/0032

  Methine dyes, e.g. cyanine dyes · CPC title